New insights into the synergism of nucleoside analogs with radiotherapy

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Lee, Michael W ^a   Parker, William B ^b,c   Xu, Bo ^b,c  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

ATM; Deoxycytidine kinase; Nucleoside analogs; Radiotherapy

Indexed keywords

ADENYLATE KINASE; CLADRIBINE; CLOFARABINE; CYCLIN DEPENDENT KINASE 1; CYTARABINE; DEOXYCYTIDINE KINASE; FLUDARABINE; GEMCITABINE; NELARABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEOSIDE ANALOG; NUCLEOSIDE DIPHOSPHATE KINASE; NUCLEOSIDE MONOPHOSPHATE KINASE; PURINE NUCLEOSIDE PHOSPHORYLASE; NUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER RADIOTHERAPY; CATABOLISM; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL SYNCHRONIZATION; CHEMOSENSITIZATION; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME MODIFICATION; ENZYME SPECIFICITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IONIZING RADIATION; NUCLEOTIDE METABOLISM; PASSIVE TRANSPORT; PHOSPHORYLATION; PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY; RADIOSENSITIZATION; RECOMBINATION REPAIR; REVIEW; AGONISTS; ANIMAL; CHEMORADIOTHERAPY; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; RADIATION RESPONSE;

ANIMALS; CHEMORADIOTHERAPY; DEOXYCYTIDINE KINASE; DNA REPAIR; HUMANS; NEOPLASMS; NUCLEOSIDES;

EID: 84884552734     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-223     Document Type: Review

References (128)

1. Montgomery JA, Hewson K. Nucleosides of 2-fluoroadenine. J Med Chem 1969, 12(3):498-504. 10.1021/jm00303a605, 5788168.
2. Huang P, Plunkett W. Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production. Biochem Pharmacol 1987, 36(18):2945-2950. 10.1016/0006-2952(87)90207-3, 3307790.
3. Pugmire MJ, Ealick SE. Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem J 2002, 361(Pt 1):1-25. 1222293, 11743878.
4. Brockman RW, Schabel FM, Montgomery JA. Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine. Biochem Pharmacol 1977, 26(22):2193-2196. 10.1016/0006-2952(77)90275-1, 563233.
5. Danhauser L, et al. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 1986, 18(2):145-152.
6. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002, 41(2):93-103. 10.2165/00003088-200241020-00002, 11888330.
7. Shewach DS, Reynolds KK, Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 1992, 42(3):518-524.
8. Krenitsky TA, et al. Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem 1976, 251(13):4055-4061.
9. Sabini E, et al. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 2003, 10(7):513-519. 10.1038/nsb942, 12808445.
10. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995, 67(2):155-186. 10.1016/0163-7258(95)00015-9, 7494863.
11. Grever M, et al. A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin Oncol 1990, 17(5 Suppl 8):39-48.
12. Nitsche M, et al. Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. J Cancer Res Clin Oncol 2012, 138(7):1113-1120. 10.1007/s00432-012-1185-3, 3605492, 22402597.
13. Consoli U, et al. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 1998, 91(5):1742-1748.
14. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 1996, 2(10):1731-1741.
15. Piro LD, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990, 322(16):1117-1121. 10.1056/NEJM199004193221605, 1969613.
16. Santana VM, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994, 84(4):1237-1242.
17. Saven A, et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995, 86(5):1710-1716.
18. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies. Leuk Lymphoma 1993, 10(Suppl):43-49.
19. Cass CE, Au-Yeung TH. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin. Cancer Res 1976, 36(4):1486-1491.
20. Carson DA, et al. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A 1979, 76(5):2430-2433. 10.1073/pnas.76.5.2430, 383615, 313056.
21. Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma 2003, 44(10):1705-1712. 10.1080/1042819031000099698, 14692522.
22. King KM, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006, 69(1):346-353.
23. Leung GP, Tse CM. The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity. Expert Opin Drug Metab Toxicol 2007, 3(5):705-718. 10.1517/17425255.3.5.705, 17916056.
24. Mackey JR, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58(19):4349-4357.
25. Wang L, et al. Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 1993, 268(30):22847-22852.
26. Hatzis P, et al. The intracellular localization of deoxycytidine kinase. J Biol Chem 1998, 273(46):30239-30243. 10.1074/jbc.273.46.30239, 9804782.
27. Johansson M, Brismar S, Karlsson A. Human deoxycytidine kinase is located in the cell nucleus. Proc Natl Acad Sci U S A 1997, 94(22):11941-11945. 10.1073/pnas.94.22.11941, 23663, 9342341.
28. Kawasaki H, et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993, 81(3):597-601.
29. Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem 1990, 265(7):4033-4040.
30. Parker WB, et al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988, 34(4):485-491.
31. Pettitt AR, Sherrington PD, Cawley JC. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 2000, 60(15):4187-4193.
32. Robertson LE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993, 81(1):143-150.
33. Seto S, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985, 75(2):377-383. 10.1172/JCI111710, 423498, 2579098.
34. Pettitt AR, et al. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol 1999, 105(4):986-988. 10.1046/j.1365-2141.1999.01448.x, 10554810.
35. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989, 49(24 Pt 1):6923-6928.
36. Fabianowska-Majewska K, et al. The influence of 2-chloro-2'-deoxyadenosine on metabolism of deoxyadenosine in human primary CNS lymphoma. Biochem Pharmacol 1995, 50(9):1379-1383. 10.1016/0006-2952(95)02018-7, 7503787.
37. Genini D, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96(10):3537-3543.
38. Hentosh P, Tibudan M. 2-Chloro-2'-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. Mol Pharmacol 1997, 51(4):613-619.
39. Cheson BD. Perspectives on purine analogues. Hematol Cell Ther 1996, 38(Suppl 2):S109-S116.
40. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994, 120(9):784-791. 10.7326/0003-4819-120-9-199405010-00010, 7908507.
41. Bonate PL, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006, 5(10):855-863. 10.1038/nrd2055, 17016426.
42. Avramis VI, Plunkett W. 2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine. Biochem Biophys Res Commun 1983, 113(1):35-43. 10.1016/0006-291X(83)90428-X, 6860342.
43. Montgomery JA, et al. Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem 1992, 35(2):397-401. 10.1021/jm00080a029, 1732556.
44. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 2002, 3(7):415-424. 10.1016/S1470-2045(02)00788-X, 12142171.
45. Zhang Y, Secrist JA, Ealick SE. The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation. Acta Crystallogr D Biol Crystallogr 2006, 62(Pt 2):133-139.
46. Zhenchuk A, et al. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009, 78(11):1351-1359. 10.1016/j.bcp.2009.06.094, 19576186.
47. Lotfi K, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999, 5(9):2438-2444.
48. Parker WB, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol 1999, 55(3):515-520.
49. Nagai S, et al. Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 2011, 71(5):1781-1791. 10.1158/0008-5472.CAN-10-1919, 3531552, 21245102.
50. Smal C, et al. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem 2006, 281(8):4887-4893.
51. Yang C, et al. Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage. Nucleic Acids Res 2012, 40(19):9621-9632. 10.1093/nar/gks707, 3479177, 22850745.
52. Parker WB, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res 1991, 51(9):2386-2394.
53. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995, 55(13):2847-2852.
54. Genini D, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 2000, 275(1):29-34. 10.1074/jbc.275.1.29, 10617581.
55. Kantarjian HM, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21(6):1167-1173. 10.1200/JCO.2003.04.031, 12637486.
56. Stackhouse MA, et al. Preclinical combination therapy of clofarabine plus radiation. Nucleosides Nucleotides Nucleic Acids 2012, 31(9):692-705. 10.1080/15257770.2012.723770, 23004932.
57. Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol 2006, 18(6):584-590. 10.1097/01.cco.0000245326.65152.af, 16988579.
58. Lambe CU, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res 1995, 55(15):3352-3356.
59. Cohen A, et al. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J Clin Invest 1978, 61(5):1405-1409. 10.1172/JCI109058, 372663, 96138.
60. Cohen A, et al. The expression of deoxyguanosine toxicity in T lymphocytes at different stages of maturation. J Immunol 1980, 125(4):1578-1582.
61. Gelfand EW, Lee JJ, Dosch HM. Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Natl Acad Sci U S A 1979, 76(4):1998-2002. 10.1073/pnas.76.4.1998, 383521, 313053.
62. Giblett ER, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975, 1(7914):1010-1013.
63. Rodriguez CO, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003, 102(5):1842-1848. 10.1182/blood-2003-01-0317, 12750168.
64. Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 1983, 61(4):660-666.
65. Prus KL, Averett DR, Zimmerman TP. Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res 1990, 50(6):1817-1821.
66. Rodriguez CO, et al. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002, 62(11):3100-3105.
67. Fyrberg A, et al. Induction of fetal hemoglobin and ABCB1 gene expression in 9-beta-D-arabinofuranosylguanine-resistant MOLT-4 cells. Cancer Chemother Pharmacol 2011, 68(3):583-591. 10.1007/s00280-010-1524-5, 21110023.
68. Rodriguez CO, Gandh V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res 1999, 59(19):4937-4943.
69. Sundaram M, et al. Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J Biol Chem 2001, 276(48):45270-45275. 10.1074/jbc.M107169200, 11584005.
70. Capizzi RL, et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1983, 1(12):763-771.
71. Verhoef V, Sarup J, Fridland A. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases. Cancer Res 1981, 41(11 Pt 1):4478-4483.
72. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 2011, 278(18):3226-3245. 10.1111/j.1742-4658.2011.08235.x, 3168698, 21740521.
73. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res 1984, 44(11):5029-5037.
74. Owens JK, et al. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992, 52(9):2389-2393.
75. Keith FJ, et al. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995, 9(1):131-138.
76. Iacobini M, et al. Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells. Biochem Pharmacol 2001, 61(8):1033-1040. 10.1016/S0006-2952(01)00548-2, 11286995.
77. Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park) 2001, 15(2 Suppl 3):11-14.
78. Carmichael J, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995, 13(11):2731-2736.
79. Pollera CF, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994, 5(2):182-184.
80. Lund B, et al. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994, 86(20):1530-1533. 10.1093/jnci/86.20.1530, 7932808.
81. Anderson H, et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994, 12(9):1821-1826.
82. Abratt RP, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994, 12(8):1535-1540.
83. Casper ES, et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12(1):29-34. 10.1007/BF00873232, 7960602.
84. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 1996, 78(3 Suppl):633-638.
85. Rauchwerger DR, et al. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000, 60(21):6075-6079.
86. Damaraju VL, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003, 22(47):7524-7536. 10.1038/sj.onc.1206952, 14576856.
87. Heinemann V, et al. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988, 48(14):4024-4031.
88. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15(6):875-890. 10.1038/sj.leu.2402114, 11417472.
89. Plunkett W, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995, 22(4 Suppl 11):3-10.
90. Huang P, et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51(22):6110-6117.
91. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995, 22(4 Suppl 11):19-25.
92. Heinemann V, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 1990, 38(4):567-572.
93. Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J Gastrointest Surg 2004, 8(8):1072-1078. 10.1016/j.gassur.2004.09.054, 15585396.
94. Nabhan C, et al. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther 2002, 1(13):1221-1227.
95. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004, 4(9):737-747.
96. Cariveau MJ, et al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. Int J Radiat Oncol Biol Phys 2008, 70(1):213-220. 10.1016/j.ijrobp.2007.09.012, 18037589.
97. Gregoire V, et al. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. Radiother Oncol 2002, 63(3):329-338. 10.1016/S0167-8140(02)00106-8, 12142097.
98. Latourette HB, Lawton RL. Combined Radiation and Chemotherapy. JAMA 1963, 186:1057-1060. 10.1001/jama.1963.03710120039008, 14061412.
99. Shewach DS, et al. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994, 54(12):3218-3223.
100. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007, 25(26):4043-4050. 10.1200/JCO.2007.11.5287, 17827452.
101. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008, 27(50):6522-6537. 10.1038/onc.2008.316, 18955977.
102. Wachters FM, et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003, 57(2):553-562. 10.1016/S0360-3016(03)00503-0, 12957269.
103. van Putten JWG, et al. End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res 2001, 61(4):1585-1591.
104. Latz D, et al. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998, 41(4):875-882. 10.1016/S0360-3016(98)00105-9, 9652852.
105. Lawrence TS, et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). Clin Cancer Res 1997, 3(5):777-782.
106. Gregoire V, et al. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol 1998, 73(5):511-520. 10.1080/095530098142059, 9652808.
107. Taricani L, et al. Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase. Cell Cycle 2010, 9(24):4876-4883. 10.4161/cc.9.24.14155, 21131780.
108. Yamauchi T, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001, 7(11):3580-3589.
109. Bulgar AD, et al. Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia. Leukemia 2010, 24(10):1795-1799. 10.1038/leu.2010.166, 20811400.
110. Csapo Z, et al. Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes. Biochem Pharmacol 2003, 65(12):2031-2039. 10.1016/S0006-2952(03)00182-5, 12787883.
111. Pauwels B, et al. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer 2006, 6:142. 10.1186/1471-2407-6-142, 1513392, 16734894.
112. Sigmond J, et al. Enhanced activity of deoxycytidine kinase after pulsed low dose rate and single dose gamma irradiation. Nucleosides Nucleotides Nucleic Acids 2006, 25(9-11):1177-1180.
113. Smal C, et al. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells. Biochem Pharmacol 2004, 68(1):95-103. 10.1016/j.bcp.2004.02.031, 15183121.
114. Smal C, et al. Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes. Cancer Lett 2007, 253(1):68-73. 10.1016/j.canlet.2007.01.013, 17350163.
115. Smal C, et al. Casein kinase 1delta activates human recombinant deoxycytidine kinase by Ser-74 phosphorylation, but is not involved in the in vivo regulation of its activity. Arch Biochem Biophys 2010, 502(1):44-52. 10.1016/j.abb.2010.07.009, 20637175.
116. Ubersax JA, et al. Targets of the cyclin-dependent kinase Cdk1. Nature 2003, 425(6960):859-864. 10.1038/nature02062, 14574415.
117. Amsailale R, et al. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells. Biochem Pharmacol 2012, 84(1):43-51. 10.1016/j.bcp.2012.03.022, 22490700.
118. McSorley T, et al. Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues. FEBS Lett 2008, 582(5):720-724. 10.1016/j.febslet.2008.01.048, 2636680, 18258203.
119. Lamba JK, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007, 323(3):935-945. 10.1124/jpet.107.128595, 17855478.
120. Kocabas NA, et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008, 36(9):1951-1959. 10.1124/dmd.108.020925, 3066084, 18556440.
121. Li L, et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009, 4(11):e7765. 10.1371/journal.pone.0007765, 2770319, 19898621.
122. Ryu JS, et al. Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin. Oncol Res 2012, 20(1):25-30. 10.3727/096504012X13425470196137, 23035362.
123. Ohmine K, et al. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. Pharm Res 2012, 29(7):2006-2016. 10.1007/s11095-012-0728-2, 22419259.
124. Saiki Y, et al. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun 2012, 421(1):98-104. 10.1016/j.bbrc.2012.03.122, 22490663.
125. Rossolillo P, et al. Retrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activation. PLoS Genet 2012, 8(8):e1002904. 10.1371/journal.pgen.1002904, 3426553, 22927829.
126. Hazra S, et al. Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release. Biochemistry 2011, 50(14):2870-2880. 10.1021/bi2001032, 3071448, 21351740.
127. Neschadim A, et al. Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther 2012, 20(5):1002-1013. 10.1038/mt.2011.298, 3345984, 22273576.
128. Hazra S, et al. Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. Biochemistry 2009, 48(6):1256-1263. 10.1021/bi802062w, 2701478, 19159229.